'); slot2 = googletag.defineSlot('/21804779673/hpe_live/mpu1', [[300, 600], [300, 250], [300, 1000]], 'div-gpt-ad-1560526566997-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot3 = googletag.defineSlot('/21804779673/hpe_live/mpu2', [300,250], 'div-gpt-ad-1560784220575-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot4 = googletag.defineSlot('/21804779673/hpe_live/mpu3', [300,250], 'div-gpt-ad-1560784251022-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot5 = googletag.defineSlot('/21804779673/hpe_live/mpu4', [300, 250], 'div-gpt-ad-1563274753432-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/slider', [1, 1], 'div-gpt-slider').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinleft', [146, 900], 'div-gpt-ad-1679485212314-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinright', [146, 900], 'div-gpt-ad-1679485314324-0').addService(googletag.pubads()); slot1 = googletag.defineSlot('/21804779673/hpe_live/leaderboard', [[970, 250], [728, 90]], 'div-gpt-ad-1579859448100-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/footer', [728, 90], 'div-gpt-ad-1563274691467-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/Overlay', [640, 480], 'div-gpt-ad-1642681358066-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/stickyfoot', [ [970, 250], [728, 90] ], 'dfp_stickyfooter').addService(googletag.pubads()); var targeturl="drug-development"; console.log("DFP set url-hpe='"+targeturl+"'"); googletag.pubads().collapseEmptyDivs(); googletag.pubads().enableSingleRequest(); // googletag.pubads().disableInitialLoad(); // BDG 03.03.2021 googletag.pubads().enableLazyLoad({ fetchMarginPercent: 0, // When the slot enters the viewport. renderMarginPercent: 0, }); // START OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.pubads().addEventListener('impressionViewable', function(event) { var slot = event.slot; if (slot.getTargeting(REFRESH_KEY).indexOf(REFRESH_VALUE) > -1) { setTimeout(function() { googletag.pubads().refresh([slot]); }, SECONDS_TO_WAIT_AFTER_VIEWABILITY * 1); } }); // END OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.enableServices(); }); //--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(''); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();});

This site is intended for health professionals only

Home > News > Drug development > Pfizer claims rights on new drug

Published on 13 May 2010

Share this story:

Pfizer claims rights on new drug

teaser

The rights to a drug which could fight a type of high blood pressure have been won by Pfizer, the firm has announced.

Terguride is an experimental drug to treat pulmonary arterial hypertension currently being tested by the Swiss firm Ergonex.

Pfizer struck a deal with the firm for the rights to terguride worldwide with the exception of Japan, and will cover the costs of completing mid-stage trials.

Japan has already approved the drug to treat the hormone disorder hyperprolactinemia, which can cause infertility.

Pulmonary arterial hypertension is a progressive disease with no cure that affects lung arteries and the right side of the heart.

Subject to eventual approval, Ergonex will receive royalties on sales.

As a drug treating a rare disease, the EU and US offer terguride “orphan drug status”, which will mean tax incentives and market exclusivity for Pfizer.

Copyright Press Association 2010
Pfizer

Pfizer claims rights on new drug

Most read